Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it



Area soci
Non possiedi o non ricordi la password!
Clicca qui

Articoli con TAG: sepsi

Approfondimenti necessari sul liquido cerebro spinale
Insights on the cerebrospinal fluid
<p>The human parechoviruses (HPeV) have recently been recognized as emerging pathogenic microorganisms causing a broad pattern of diseases including sepsis and meningitis in children. A born-at-term, 33-day-old child, was admitted to the hospital with fever, irritability, and loss of appetite. Results of physical examination and routine blood chemistry were unremarkable (no lung rales or skin rashes; normal hemoglobin and leukocyte and platelets counts) with the only exception of an elevated procalcitonin serum level. Examination of the patient&rsquo;s cerebrospinal fluid (CSF) showed pleocytosis, normal glycorrhachia and a mild increase of proteins. Blood and CSF cultures were negative. When tested with a commercial multiplex PCR technology (FILMARRAY&reg;- Biomerieux), CSF turned out positive for the HPeV. Rapid identification of HPeV may contribute to reduce the laboratory turnaround time and improve clinical management. HPeV should be included in the differential diagnosis of young children with central nervous system symptoms and sepsis-like illness.</p>
Biochimica Clinica ; 17(1)
Casi Clinici - Case Report
 
La procalcitonina in terapia intensiva: dubbi che rimangono?
Procalcitonin in intensive care: unresolved doubts
<p>Procalcitonin (PCT), a test marketed by some twenty years, is available virtually on all the platforms present in clinical laboratories of any size, even if its precise role is still debated. PCT is requested especially by intensive care units (ICU) and it has been included in algorithms to guide the administration of antibiotics (AB). However, several reports concluded that, despite a theoretical physio-pathological basis, there is no unambiguous evidence that the inclusion of PCT in algorithms is effective to guide AB treatment. In 2012 the Cochrane Collaboration concluded that &ldquo;Further high-quality research is needed to confirm the safety of this approach in intensive care. Moreover, future studies should also establish cost-effectiveness by considering country-specific costs of procalcitonin measurement and potential savings in consumption of antibiotics and other healthcare resources, as well as secondary cost savings due to lower risk of side effects and reduced antimicrobial resistance&rdquo;. In 2015, the National Institute for Clinical Heath Excellence concluded that the test is promising but there is still insufficient evidence to recommend its use to guide the AB treatment of sepsis in ICU. Recently, in a paper published in the Clinical Chemistry journal among the limiting factors preventing widespread use of PCT in sepsis and antibiotic stewardship it was included: the limited availability (and high cost) of PCT, the reluctance showed by clinicians to deescalate antibiotics based on PCT results and the uncertainty about the generalizability of previous studies results. The duration of therapy generally tends to be longer compared to what was recommended by guidelines, and PCT-guided antibiotic discontinuation may be of little benefit in hospitals where duration of therapy is already optimized.</p>
Biochimica Clinica ; 42(2) 146-151
Opinioni - Opinions
 
Procalcitonina in Terapia Intensiva: più certezze che dubbi
Procalcitonin in intensive care unit: more confidence than hesitation
Biochimica Clinica ; 42(2) 180-182
Lettere all'Editore - Letters to the Editor